Amgen
Biologics & Biosimilars · Prescription Drugs

Amgen revenue, results and funding

Amgen filed revenue of $36.8B for 2025.

Data updated Nov 18, 2026 · Back to the company report
$36.8BRevenue, 2025
$7.7BNet income, 2025

Results by year

YearRevenueNet incomeTotal assetsLANG_CR_S_M_TAX_PAIDLANG_CR_S_M_TAX_EXPENSELANG_CR_S_M_DIVIDENDSLANG_CR_S_M_BUYBACKSLANG_CR_S_M_CAPEXLANG_CR_S_M_SBCLANG_CR_S_M_RNDLANG_CR_S_M_OPERATING_INCOMELANG_CR_S_M_CASHLANG_CR_S_M_DEBTLANG_CR_S_M_ACQUISITIONS
2025$36.8B$7.7B$90.6B$4.3B$1.3B$5.1B$0$1.9B$494M$7.3B$9.1B$9.1B$50B$53M
2024$33.4B$4.1B$91.8B$2.9B$519M$4.8B$200M$1.1B$530M$6B$7.3B$12B$56.5B$0
2023$28.2B$6.7B$97.2B$3.4B$1.1B$4.6B$0$1.1B$431M$4.8B$7.9B$10.9B$63.2B$27B
2022$26.3B$6.6B$65.1B$2.4B$794M$4.2B$6.4B$936M$401M$4.4B$9.6B$7.6B$37.4B$3.8B
2021$26B$5.9B$61.2B$1.9B$808M$4B$5B$880M$341M$4.8B$7.6B$8B$33.2B$2.5B
2020$25.4B$7.3B$62.9B$1.4B$869M$3.8B$3.5B$608M$330M$4.2B$9.1B$6.3B$32.9B$0
2019$23.4B$7.8B$59.7B$1.9B$1.3B$3.5B$7.7B$618M$308M$4.1B$9.7B$6B$27B$13.6B
2018$23.7B$8.4B$66.4B$1.9B$1.2B$3.5B$17.8B$738M$311M$3.7B$10.3B$6.9B$29.5B−$195M
2017$22.8B$2B$80B$1.5B$7.6B$3.4B$3.2B$664M$329M$3.6B$10B$3.8B$34.2B$19M
2016$23B$7.7B$77.6B$1.1B$1.4B$3B$3B$738M$311M$3.8B$9.8B$3.2B$30.2B$0
2015$21.7B$6.9B$71.4B$919M$1B$2.4B$1.9B$594M$322M$4.1B$8.5B$4.1B$29.2B$359M
2014$20.1B$5.2B$69B$269M$427M$1.9B$138M$718M$408M$4.3B$6.2B$3.7B$30.2B$165M
2013$18.7B$5.1B$66.1B$321M$184M$1.4B$832M$693M$403M$4.1B$5.9B$3.8B$29.6B$9.4B
2012$17.3B$4.3B$54.3B$502M$664M$1.1B$4.6B$689M$362M$3.4B$5.6B$3.3B$26.5B$2.4B
2011$15.6B$3.7B$48.9B$595M$467M$500M$8.3B$567M$341M$3.2B$4.3B$6.9B$21.4B$701M
Sources: SEC

How to cite

Amgen, Financials. Alion, Nov 18, 2026. https://alion.io/company/amgen/financials

.json · .md · CC BY-SA 4.0